

RNA based vaccine

Pfizer- BioNTech

Trial/Registry	Phase	Vaccine	Comparator	Sample size	Population/Centre/Location	Date of study	Follow-up (months)	Variant exposure (resource)	Funding	Conflict of interest
Walsh 2020 Walsh E, N Engl J Med, 2020 NCT04368728	Phase 1	BNT162b2 2 IM 30 µg (D0/21)	Placebo	195	Healthy adults/Multicenter/United States	05/04/2020 to 06/22/2020	1.68	No information (report & outbreak.info)	Private (BioNTech, Pfizer)	Yes
Frenck 2021 Frenck R, N Engl J Med, 2021, NCT04368728,	Phase 3	BNT162b2 2 IM of 3mcg (D0/21)	Placebo	2264	Adolescents 12-15y/Multicenter/United States	10/15/2020 to 12/01/2021	4.7	No information (report & outbreak.info)	Private (BioNTech, Pfizer)	Yes
Thomas 2021 Thomas S, N Engl J Med, 2021, NCT04368728	Phase 2-3	BNT162b2 2 IM of 3mcg (D0/21)	Placebo	44,165	Children, adolescent&adults/Multicenter/Multinational	07/27/2020 to 01/11/2021	6	Beta variant – dominant in South Africa (report)	Private (BioNTech, Pfizer)	Yes

ModernaTX

Ali 2021 Ali K, N Engl J Med, 2021, NCT04649151	Phase 2-3	mRNA-1273 - 2 IM doses of 100 mcg (D0/D28)	Placebo	3,732	Healthy adolescents/Multicenter/United States	12/09/2020 to 02/28/2021	NR	Alpha: 0-20% (outbreak.info)	Mixed (Moderna; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA))	Yes
El Sahly 2021 El Sahly HM, N Engl J Med, 2021, NCT04470427,	Phase 3	mRNA-1273 - 2 IM doses of 100 mcg (D0/D28)	Placebo	30,415	Healthy adults/Multicenter/United States	07/27/2020 to 10/23/2020	5.3	Low circulation of variant of concern (report)	Mixed (Moderna; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA))	Yes

CureVac AG

Kremsner 2021 Kremsner P, SSRN, 2021, NCT04652102, EudraCT 2020-003998-22	Phase 2-3	CVnCoV - 2 IM doses of 12 mcg (D0/28)	Placebo	39,529	Adults/Multicenter/ Multinational	12/11/2020 to 04/12/2021	6.2	-Europe: 92% Alpha -Latin America: 13% Alpha; 23% Gamma 28% Lambda (C.37) 19% B.1.621 (Colombia) (report)	Mixed (The German Federal Ministry of Education and Research (BMBF), CureVac AG)	Yes
---	-----------	---------------------------------------	---------	--------	--------------------------------------	--------------------------	-----	--	--	-----

Non replicating viral vector

Astra Zeneca - University of Oxford

Asano 2021 Asano M, Int J Infect Dis, 2021, NCT04568031,	Phase 1-2	ChAdOx1 - 2 IM doses of 5×10^{10} vp (D0/28)	Placebo	256	Adults/Multicenter/Japan	08/01/2020 to 02/24/2021	1.9	Alpha: 0-10% Beta and Gamma: 0-1% (outbreak.info)	Private (AstraZeneca)	Yes
Clemens 2021 Clemens S, Nat. Commun., 2021	Phase 3	ChAdOx1- 2 IM doses of $3.5-6.5 \times 10^{10}$ vp, 4 to 12 weeks apart	1 IM dose of Men ACWY control vaccine and 1 IM dose of normal saline placebo, 4 to 12 weeks apart	10,416	Adults/Multicenter/Brazil	2020/06/23 to 2020/12/01	8.27	Wild type and Gamma variant (report)	Mixed (UKRI, NIHR, Wellcome Trust, CEPI, Lemann Foundation, Rede D'Or, and Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, and AstraZeneca)	Yes

Emary 2021 Emary K, Lancet, 2021, NCT04400838,	Phase 2-3	ChAdOx1 - 2 IM doses of 5×10^{10} vp (D0/28)	MenACWY - 2 IM doses of MenACWY vaccine (D0/28)	10,673	People in close contact with COVID-19 patients /Multicenter/UK	05/31/2020 to 11/13/2020	4.9	Alpha dominant (report) Alpha: 0-10% (outbreak.info)	Mixed (UK Research and Innovation, Engineering and Physical Sciences Research Council, Coalition for Epidemic Preparedness Innovations, NIHR, Medical Research Council and Wellcome Trust Core Award.)	Yes
Falsey 2021 Falsey A, N Engl J Med, 2021, NCT04516746	Phase 3	ChAdOx1 - 2 IM doses of 5×10^{10} vp (D0/28)	Placebo	32,451	Adults and elderly at high risk of exposure/Multicenter/Chile, Peru, USA	08/28/2020 to 01/15/2021	6.27	Small number of variants of concern (report)	Mixed (AstraZeneca; the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority; the Infectious Diseases Clinical Research Consortium, National Institute of Allergy and Infectious Diseases, part of the NIH)	Yes
Kulkarni 2021 Kulkarni P, SSRN, 2021, CTRI/2020/08/027170,	Phase 2-3	SII-ChAdOx1 nCoV-19 - 2 IM doses of 5×10^{10} vp (D0/28)	Placebo Adjuvant	1,200	Healthy Adults/Multicenter / India	08/25/2020 to 10/31/2020	6	Alpha: <1% Delta: 0-2% (outbreak.info)	Mixed (Serum Institute of India Pvt Ltd, Indian Council of Medical Research, AstraZeneca)	Yes
Madhi 2021 Madhi S, Lancet, 2021, NCT04444674; PACTR202006922165132	Phase 1-2	ChAdOx1 - 2 IM doses of 5×10^{10} vp (D0/28)	Placebo	104	Adults living with HIV /Multicenter/South Africa	08/17/2020 to 11/12/2020	2	Beta variant dominant (report)	Public/non profit (The Bill & Melinda Gates Foundation, South African Medical Research Council, UK Research and Innovation, UK National Institute for Health Research)	Yes

Madhi 2021 Madhi S, N Engl J Med, 2021, NCT04444674	Phase 1-2	ChAdOx1 - 2 IM doses of 5×10^{10} vp (D0/28)	Placebo	2,026	Adults/Multicenter/South Africa	06/24/2020 to 11/08/2020	6.7	Beta variant: 95.1% (sample of 42 participants) (report)	Mixed (UK Research and Innovation, The Bill and Melinda Gates Foundation and South African Medical Research Council)	Yes
Voysey 2021 Voysey M, Lancet, 2021, NCT04324606; ISRCTN89951424; NCT04400838; NCT04444674	Phase 1/2/3	ChAdOx1 (low/standard or standard/standard) - 2 IM doses of 2.2 or 5.5×10^{10} vp ChAdOx1 (D0/28)	MenACWY vaccine or saline placebo	24,422	Adults/Multicenter/Brazil, South Africa, UK	04/23/2020 to 12/06/2020	3.9	-Brazil: Gamma 0-2% -South Africa: Beta: 0-85% -UK: Alpha 0-10% (outbreak info)	Mixed (UKRI, NIHR, CEPI, the Bill & Melinda Gates, Lemann Foundation, Rede D'OR, the Brava and Telles Foundation, Thames Valley and South Midland's, and Astra Zeneca)	Yes
Gamaleya Research Institute										
Logunov 2021 Logunov D, Lancet, 2021, NCT04530396	Phase 3	Gam-COVID-Vac - 1 IM dose of rAd26-S 10^{11} vp followed by 1 IM dose of rAd5-S 10^{11} vp (D0/21)	Placebo (Vaccine buffer composition)	21977	SARS-CoV-2- and HIV infection-free adult volunteers/Multicenter/ Russia	09/07/2020 to 11/24/2020	2.6	No information (report & outbreak.info)	Mixed (Moscow City Health Department, Russian Direct Investment Fund, Sberbank, and RUSAL)	Yes
Janssen Pharmaceutical Companies										
Sadoff 2021a Sadoff J, N Engl J Med, 2021, NCT04436276	Phase 1-2	Ad26.COVS.S - 1 or 2 IM low dose of 5×10^{10} vp (D0/56) Ad26.COVS.S - 1 or 2 IM high dose of 1×10^{11} vp Ad26.COVS.S (D0/56)	Placebo	810	Healthy adults and elderly Multicenter/Belgium, USA	07/22/2020 to 08/24/2020	2.3	No information (report & outbreak.info)	Mixed (Johnson and Johnson, Department of Health and Human Services Biomedical Advanced Research and Development Authority)	Yes

Sadoff 2021b Sadoff J, N Engl J Med, 2021, NCT04505722	Phase 3	Ad26.COV2.S - 1 IM dose Ad26.COV2.S (D0)	Placebo	44325	Adults/ Multicenter/ Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States	09/21/2020 (end date not reported)	1.8	-Brazil: Wuhan-Hu-1 including the D614G mutation (30.6%) and Wuhan-Hu-1 including the E484K mutation (69.4%) -South Africa: beta 96.4% -United States: 71.7% Wuhan-Hu-1 including the D614G mutation (report)	Mixed (Janssen Research and Development, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, NIAID, National Institutes of Health.)	Yes
--	---------	---	---------	-------	--	------------------------------------	-----	--	--	-----

Inactivated Virus

Sinovac

Zhang 2020 Zhang Y, Lancet Infect Dis, 2020 , NCT04352608	Phase 1	CoronaVac - 2 IM doses of 3mcg or 6 mcg (D0/14 or (D0/28)	Placebo (aluminum hydroxide)	144	Healthy adults/ Multicenter/ China	04/16/2020 to 04/25/2020	1.4	No information (report & outbreak.info)	Mixed (National Key Research and Development Program, Beijing Science and Technology Program)	Yes
Zhang 2020 Zhang Y(2), Lancet Infect Dis, 2020, NCT04352608	Phase 2	CoronaVac - 2 IM doses of 3mcg or 6 mcg (D0/14 or (D0/28)	Placebo (aluminum hydroxide)	600	Healthy adults/Single center/ China	03/05/2020 to 05/05/2020	1.4	No information (report & outbreak.info)	Mixed (National Key Research and Development Program, Beijing Science and Technology Program)	Yes

Bueno 2021 Bueno S, Clin Infect Dis, 2021, NCT04651790,	Phase 3	CoronaVac - 2 IM doses of 3 mcg (D0/14)	Adjuvant (D0/14)	434	People in close contact with COVID-19 patients, Healthcare workers /Multicenter/Chile	11/27/2020 to 02/10/2021	1.4	Wild-type strains (original L strain) and the B.1.1.7 strain	Public/non-profit (Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.)	Yes
Han 2021 Han B, SSRN, 2021, NCT04551547	Phase 1-2	CoronaVac - 2 IM doses of 1.5 mcg or 3mcg(D0/28)	Placebo Adjuvant	552	Healthy children and adolescents aged /Single center/China	10/31/2020 to 12/30/2020	4.1	No information (report & outbreak.info)	Public/non profit (Chinese National Key Research and Development Program and Beijing Science and Technology Program)	Yes
Fadlyana 2021 Fadlyana E, Vaccine, 2021, NCT04508075 ; INA-WXFM0YX	Phase 3	CoronaVac - 2 IM doses of 3mcg (D0/14)	Placebo	1620	Healthy adults/Single center / Indonesia	08/11/2020 to 10/21/2020	3	No information (report & outbreak.info)	Mixed (PT Bio Farma and Sinovac Life Sciences Co., Ltd.)	Yes
Palacios 2021 Palacios R, SSRN, 2021, NCT04456595,	Phase 3	CoronaVac - 2 IM doses of 3mcg (D0/14)	Placebo Adjuvant	12408	Healthcare professionals with or without previous COVID-19 infection caring for COVID-19/Multicenter/ Brazil	07/21/2020 to 12/16/2020	12	P.2 variant (report)	Public/non-profit (Fundação Butantan, Instituto Butantan, and São Paulo Research Foundation (FAPESP))	Yes
Tanriover 2021 Tanriover M, Lancet, 2021, NCT04582344,	Phase 3	CoronaVac - 2 IM doses of 3mcg (D0/14)	Placebo Adjuvant	10,218	Healthy healthcare workers and adults /Multicenter/ Turkey	09/15/2020 to 01/06/2021	6	Alpha: 2-40% (outbreak.info)	Public/non-profit (Turkish Health Institutes Association (TUSEB))	Declared, No conflict of interest

Wu 2021 Wu Z, Lancet Infect Dis, 2021, NCT04383574	Phase 1-2	CoronaVac - 2 IM doses of 1.5 mcg or 3mcg or 6mcg (D0/28)	Aluminum hydroxide placebo	422	Elderly/Single center /China	05/22/2020 to 06/15/2020	1.8	No information (report & outbreak.info)	Public/non-profit (The National Key Research and Development Program; the Beijing Science and Technology Program)	Yes
Sinopharm-Wuhan										
Al Kaabi 2021 Al Kaabi N, JAMA, 2021, NCT04510207, ChiCTR2000034780	Phase 3	-SARS-CoV-2 strain WIV04 - 2 IM doses of 5 mcg (D0/22) -SARS-CoV-2 strain HBO2 - 2 IM doses of 4 mcg (D0/22)	Placebo Adjuvant	40,411	Healthy adults free of known COVID-19 or HIV infection/ Multicenter / United Arab Emirates, Bahrain	07/16/2020 to 12/20/2020	5	Alpha: 0-60% (outbreak.info)	Mixed (National Key Research and Development Project of China, China National Biotec Group Company Limited)	Yes
Guo 2021 Guo W, EclinicalMedicine, 2021, ChiCTR2000031809	Phase 1-2	-Inactivated vaccine - 3 IM doses of 2.5,5, or 10mcg mcg (D0/28/56) -Inactivated vaccine - 2 IM doses of 5 mcg (D0/14), (D0/21), or (D0/28) -Inactivated vaccine - 1 IM dose of 10 mcg (D0)	Placebo Adjuvant	1,120	Healthy adults/ Multicenter / China	04/12/2020 to 05/17/2020	4.8	No information (report & outbreak.info)	Public/nonprofit (National Program on Key Research Project of China; Major Science and Technology Project of the National New Drug Development of China)	Yes
Sinopharm-Beijing										
Al Kaabi 2021 Al Kaabi N, JAMA, 2021, NCT04510207 ; ChiCTR2000034780,	Phase 3	-SARS-CoV-2 strain WIV04 - 2 IM doses of 5 mcg (D0/22) -SARS-CoV-2 strain HBO2 - 2 IM doses of 4 mcg (D0/22)	Placebo Adjuvant	40,411	Healthy adults free of known COVID-19 or HIV infection/ Multicenter / United Arab Emirates, Bahrain	07/16/2020 to 12/20/2020	5	Alpha: 0-60% (outbreak.info)	Mixed (National Key Research and Development Project of China, China National Biotec Group Company Limited)	Yes

Xia 2020 Xia S, Lancet Infect Dis, 2020, ChiCTR2000032459	Phase 2	-BBIBP-CorV - 2 IM doses of 8 mcg (D0) -BBIBP-CorV - 2 IM doses of 4 mcg (D0/D14) -BBIBP-CorV - 2 IM doses of 4 mcg (D0/D21) -BBIBP-CorV - 2 IM doses of 4 mcg (D0/D28)	Placebo Adjuvant	448	Healthy SARS-CoV-2 serology negative adults 18-59 years old in a single centre in China	05/18/2020 to 07/30/2020	1	No information (report & outbreak.info)	Mixed (National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan. The China National Biotech Group and the Beijing Institute of Biological Products provided the study product, and oversaw all trial operations.)	Yes
Xia 2021 Xia S , Lancet, 2021, ChiCTR2000032459	Phase 1-2	-BBIBP-CorV - 3 IM doses of 2 mcg (D0/28/56) -BBIBP-CorV - 3 IM doses of 4 mcg (D0/28/56) -BBIBP-CorV - 3 IM doses of 8 mcg (D0/28/56)	Placebo Adjuvant	1008	Healthy children and adolescents aged 3 to 17 years free from SARS-CoV-2 infection and antibodies at a single centre in China	08/14/2020 to 09/24/2020	2.9	No information (report & outbreak.info)	Private (Beijing Institute of Biological Products)	Yes
Bharat Biotech										
Ella 2021a Ella R, Lancet Infect Dis, 2021, NCT04471519 ; CTRI/2	Phase 1	BBV152 nCoV-19 vaccine + Algel-IMDG adjuvant - 2 IM doses of 6-mcg or 3mcg + 0.5mL Algel-IMDG (alum) adjuvant (D0/14)	Algel (alum) - 0.5mL (D0/14)	375	Healthy adults/ Multicenter/ India	07/13/2020 to 07/30/2020	6.4	No information (report & outbreak.info)	Private (Bharat Biotech International Limited)	Yes
Ella 2021b Ella R, medRxiv, 2021, NCT04641481.	Phase 3	BBV152 - 2 IM doses of 6 mcg (D0/28)	Placebo Adjuvant	25778	Healthy adults/ Multicenter/ India	11/16/2020 to 01/07/2021	12	Alpha, Delta, Kappa: <1% (report, table 3)	Mixed (Bharat Biotech International Limited and the Indian Council of Medical Research)	Yes

Protein subunit

Novavax

Keech 2020 Keech C, N Engl J Med, 2020, NCT04368988	Phase 1	-NVX-CoV2373 – 2 IM doses 25 µg NVX-CoV2373/0 µg Matrix-M1 (D0/21) – 2 IM doses 5 µg NVX-CoV2373/50 µg Matrix-M1 (D0/21) – 2 IM doses 25 µg NVX-CoV2373/50 µg Matrix-M1 (D0/21) – 1 IM dose 25 µg NVX-CoV2373/50 µg Matrix-M1, followed by placebo dose (D0/21)	Placebo	134	Healthy adults/ Multicenter / Australia	05/27/2020 to 06/06/2020	1.15	No information (report & outbreak.info)	Mixed (Novavax/Funded by the Coalition for Epidemic Preparedness Innovations/ vaccine NVX-CoV2373, developed by Novavax and manufactured at Emergent Biosolutions (Rockville,Maryland))	Yes
Dunkle 2021 Dunkle L M, medRxiv, 2021, NCT04611802	Phase 3	NVX-CoV2373 – 2 IM doses of 5 mcg (D0/21)	Placebo	13,181	Adult and elderly/ Multicenter/Mexico, USA	12/27/2020 to 02/18/2021	2	Alpha: 88.6% sample of 35 sequenced (report)	Mixed (Funded by Novavax and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health)	Yes
Formica 2021 Formica N, PLoS Med, 2021, NCT04368988,	Phase 2	NVX-CoV2373 5mcg 2 doses 5mcg 1 dose 25mcg 2 doses 25mcg 1 dose	Placebo	1,288	Adults/Multicenter/Australia, USA	08/24/2020 to 09/25/2020	1.2	Beta: 92.7% (report)	Mixed (Coalition for Epidemic Preparedness Innovations; Novavax Inc)	Yes
Heath 2021 Heath P, N Engl J Med, 2021, NCT04583995; EudraCT 2020-004123-16	Phase 3	NVX-CoV2373 - 2 IM doses 5 mcg (D0/21)	Placebo	15,187	Adults/Multicenter/UK	09/28/2020 to 11/28/2020	3	Alpha: 95% of a sample of 69 sequenced (report)	Private (Novavax, Inc)	Yes

Shinde 2021 Shinde V, N Engl J Med, 2021, NCT04533399; PACTR202009726132275	Phase 2	NVX-CoV2373 - 2 IM doses 5 mcg (D0/21) with 50 mcg Matrix-M1 adjuvant	Placebo	134	HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) Multicenter/South Africa	08/17/2020 to 11/25/2020	1.2	Beta: 92.7%	Mixed (Novavax, Bill and Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations)	yES
Instituto Finlay de Vacunas										
Toledo-Romani 2021 Toledo-Romani ME, medRxiv, 2021, RPCEC00000354	Phase 3	-FINLAY-FR-2-25 mcg - 2 IM doses of 25 mcg (D0/28) -FINLAY-FR-2-25 mcg +FR-1-50 mcg - 2 IM doses of 25 mcg + 1 IM dose of 50 mcg D0/28/56)	Placebo Adjuvant	44,031	Medically stable adults/ Multicenter/Cuba	03/08/2021 to 03/31/2021	5.2	No information in report. Can't find Cuba in outbreak.info	Public/non-profit (Finlay Vaccine Institute, Biocubafarma and Fondo Nacional de Ciencia y Tecnica)	Yes
Heterologous vaccination										
Liu 2021 Liu X, Lancet, 2021, ISRCTN69254139, EudraCT: 2020-005085-33	Phase 2	-1 IM dose of 5.5×10 ¹⁰ vp ChAdOx1 and 1 IM dose of 30 mcg BNT162b2 (D0/28) 1 IM dose of 30 mcg BNT162b2 and 1 IM dose of 5.5×10 ¹⁰ vp ChAdOx1 (D0/28)	-2 doses of ChAdOx1 -2 doses of BNT162b2	463	Adults 50+ HIV negative/ Multicenter/UK	02/11/2021 to 02/26/2021	2	Alpha: 90-100% (outbreak.info)	Public/non profit (UK Vaccine Task Force (VTF) and National Institute for Health Research (NIHR))	Yes
Li 2021 Li J, medRxiv, 2021, NCT04892459	Phase 4	CoronaVac/Ad5-vectored - 1 IM dose CoronaVac + 1 IM dose Convidecia 5x10 ¹⁰ vp, 1-3 months later	2 doses of CoronaVac	100	Adults/Single center/ China	05/25/2021 to 05/26/2021	1	Alpha: 60% Delta: 80% (outbreak.info)	Public/non-profit (National Natural Science Foundation of China)	Yes
Boosters										
Bonelli 2021 Bonelli M, medRxiv, 2021, EudraCT 2021-002348-57	NR	ChAdOx1 booster, 1 IM booster dose >4 weeks after full primary vaccination schedule	BNT162b2 or mRNA-1273 booster	60	Adults under current rituximab therapy/Single center/Austria	05/25/2021 to 07/08/2021	1	Alpha : 0-85% Delta : 0-80% Gamma : 0-9% (outbreak.info)	Public/non profit (Medical University of Vienna; City of Vienna; Medical-Scientific fund of the Mayor of the federal capital Vienna.)	Yes

Hall 2021 Hall VG, N Engl J Med, 2021	Phase 4	A third IM booster dose of mRNA-1273 vaccine, 2 months after the second dose	1 IM dose of saline placebo, 2 months after the second dose of mRNA-1273 vaccine	120	Solid organ transplant recipients with no previous diagnosis of COVID-19 who has previously received two doses of mRNA-1273 at a single center in Canada	2021/05/25 to 2021/06/03	1	Delta: 10% Alpha: 60% (outbreak.info)	Public/non profit (The Ajmera Transplant Centre and the Di Poce Transplant Fund, University Health Network, University of Toronto)	Yes
Li 2021 Li J, medRxiv, 2021, NCT04892459	Phase 4	CoronaVac/boost Ad5-vectored - 2 IM doses CoronaVac + 1 IM booster dose Convidecia 5×10 ¹⁰ vp, 3-6 months later	CoronaVac boost	200	Adults/Single center/China	05/25/2021 to 05/26/2021	1	Alpha: 60% Delta: 80% (outbreak.info)	Public/non-profit (National Natural Science Foundation of China)	Yes
Mok 2021 Mok C K P, medRxiv, 2021, NCT04611243	NR	CoronaVac/Boost CoronaVac - 2 IM doses of CoronaVac 28 days apart + 1 IM dose of CoronaVac 116 days later (mean)	CoronaVac/Boost BNT162b2	80	Adults/Multicenter/China	08/18/2021 to 10/26/2021	5.8	Delta (outbreak.info)	Public/non-profit (the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease, Guangdong Province International Scientific and Technological Cooperation Projects, the National Research Foundation of Korea, US National Institutes of Health, NSFC/ (RGC) Joint Research Scheme)	Declared, No conflict of interest

Sablerolles 2021 Sablerolles R, medRxiv, 2021, NCT04927936	Phase 3	- Ad26.COVS/Ad26.COVS, 1 IM dose Ad26.COVS 84 days (-7/+21) after primary Ad26.COVS vaccination -Ad26.COVS/m-RNA-1273, 1 IM dose mRNA-1273 84 days (-7/+21) after primary Ad26.COVS vaccination -Ad26.COVS/BNT162b2, 1 IM dose BNT162b2 84 days (-7/+21) after primary Ad26.COVS vaccination	Ad26.COVS/ No boost	461	Healthcare workers/ Multicenter/The Netherlands	06/25/2021 (end date not reported)	1	Alpha : 30% Delta : 40% (outbreak.info)	Public/non profit (ZonMW)	Declared, No conflict of interest
--	------------	---	------------------------	-----	--	------------------------------------	---	---	------------------------------	-----------------------------------